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26 ABSTRACT 
 
27 The 2009-2010 influenza pandemic saw many people treated with antivirals and antibiotics. 
 
28 High proportions of both classes of drugs are excreted and enter wastewater treatment plants 
 
29 (WWTPs) in biologically active forms. To date, there has been no study into the potential for 
 
30 influenza pandemic-scale pharmaceutical use to disrupt WWTP function.  Furthermore, there 
 
31 is currently little indication as to whether WWTP microbial consortia can degrade antiviral 
 
32 neuraminidase inhibitors when exposed to pandemic-scale doses.  In this study, we exposed 
 
33 an aerobic granular sludge sequencing batch reactor, operated for enhanced biological 
 
34 phosphorus removal (EBPR), to a simulated influenza-pandemic dosing of antibiotics and 
 
35 antivirals for 8 weeks.  We monitored removal of the active form of Tamiflu, oseltamivir 
 
36 carboxylate (OC), bacterial community structure, granule structure and changes in EBPR and 
 
37 nitrification performance.  There was little removal of OC by sludge and no evidence that the 
 
38 activated sludge community adapted to degrade OC.  There was evidence of changes to 
 
39 bacterial community structure and disruption to EBPR and nitrification during and after high- 
 
40 OC dosing.  This work highlights the potential for antiviral contamination of receiving waters 
 
41 and indicates the risk of destabilising WWTP microbial consortia as a result of high 
 
42 concentrations of bioactive pharmaceuticals during an influenza pandemic. 
 
43 
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43 INTRODUCTION 
 
44 Society has never been more prepared for the emergence of pandemic influenza than at 
 
45 present, due in part to the development and stockpiling of a novel class of antiviral drugs, 
 
46 neuraminidase inhibitors, notably: Tamiflu® (oseltamivir ethylester-phosphate (OP)) and 
 
47 Relenza® (zanamivir).  National stockpiling of neuramindase inhibitors began in earnest with 
 
48 the emergence of the 2009 influenza pandemic (H1N1). These stockpiles were dominated by 
 
49 Tamiflu largely owing to its relative ease of administration (tablet), as compared with 
 
50 Relenza (disc-inhaler).  Tamiflu is a prodrug which, after absorption into the blood, is 
 
51 converted to the active antiviral, oseltamivir carboxylate (OC) in the liver.  Approximately 
 
52 80% of an oral dose of Tamiflu is excreted as OC in the urine (He et al., 1999), with the 
 
53 remainder excreted as OP in the faeces.  Both the parent chemical and its bioactive metabolite 
 
54 ultimately reach the receiving wastewater treatment plants (WWTPs) where it was projected 
 
55 to reach a mean of ~2 to 12 µg L-1 during a moderate and severe pandemic respectively 
 
56 (Singer et al., submitted). 
 
57 Current evidence suggests conservation of OC as it passes through WWTPs (Accinelli et al., 
 
58 2010, Fick et al., 2007, Ghosh et al., 2010, Prasse et al., Soderstrom et al., 2010), hence, 
 
59 rivers receiving WWTP effluent will also be exposed to OC throughout a pandemic. 
 
60 Concentrations of between 293 and 480 ng OC L-1 have been recorded in rivers receiving 
 
61 WWTP effluent during the 2009 pandemic (Ghosh et al., 2010, Soderstrom et al., 2010). 
 
62 Several studies have demonstrated the potential for removal of OC from fresh water 
 
63 (amended in some cases with sediment) and activated sludge (amended in some cases with a 
 
64 granular bioplastic formulation entrapping propagules of white rot fungi) via adsorption, 
 
65 microbial degradation and indirect photolysis (Accinelli et al., 2007, Accinelli et al., 2010, 
 
66 Bartels and von Tumpling, 2008, Sacca et al., 2009).  A key factor in determining the amount 
 
67 of OC removal appears to be the length of incubation, with batch incubations of 40 days 
4 
 
68 resulting in degradation of up to 76% OC in the presence of an activated sludge inoculum 
 
69 (Accinelli et al., 2010).  However, batch experiments do not reflect the activities of a WWTP 
 
70 as the hydraulic residence time for wastewater in the activated sludge system is commonly 
 
71 only a few hours and degradation would therefore be expected to be much lower.  In a 
 
72 pandemic scenario, Tamiflu use would rapidly rise over an 8 week period as the outbreak 
 
73 spread and would follow a similarly rapid decline after the peak (Singer et al., 2007, Singer et 
 
74 al., 2008, Singer et al., submitted).  We hypothesise that the prolonged exposure of WWTP 
 
75 microbial consortia over the course of a pandemic might hasten the generation of OC- 
 
76 degraders in the activated sludge bacterial community thereby minimising the risks posed 
 
77 from widespread environmental release. 
 
78 The key processes in WWTPs (removal of organic carbon, nitrogen (N) and phosphorus (P)), 
 
79 are microbiologically mediated by activated sludge.  Activated sludge systems are constantly 
 
80 exposed to pharmaceuticals from a variety of sources (Daughton and Ternes, 1999), however, 
 
81 it remains unclear as to their effective toxicity (i.e., impact on nutrient removal performance). 
 
82 The functioning of activated sludge under a pandemic scenario is of concern given the 
 
83 projected heavy usage of not only antivirals but also antibiotics (ABs) (Singer et al., 2008, 
 
84 Singer et al., submitted). There is recent evidence that bacterial neuraminidases are important 
 
85 in biofilm formation (Parker et al., 2009, Soong et al., 2006).  Consequently, antiviral 
 
86 neuramindase inhibitors themselves may inhibit bacterial neuraminidases which could prove 
 
87 detrimental to the structure of the suspended biofilms that make up activated sludge.  Whilst 
 
88 this is yet to be fully investigated, current data indicate that the ecotoxicological risks posed 
 
89 by OC are low (Straub, 2009). 
 
90 In addition to examining the potential evolution of OC-degradation in a microbial consortium 
 
91 we aimed to investigate the effects of OC and ABs on activated sludge bacterial community 
 
92 structure and function and activated sludge biofilm structure.  We implemented a 56-day, 
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pandemic-scenario dosing regime of OC and three ABs (with different modes of action): 
amoxicillin (cell-wall-synthesis inhibition), erythromycin (protein-synthesis inhibition) and 
levofloxacin (DNA-replication inhibition), in a laboratory-scale sequencing batch reactor 
(SBR) operated for granular enhanced biological phosphorus removal (EBPR).  The three 
antibiotics selected for this study are among the most frequently employed antibiotics, within 
their class, for the treatment of influenza-associated bacterial pneumonia (Lim et al., 2007). 
An additional high OC dosing period without ABs was employed to examine OC toxicity and 
WWTP function in the absence of the presumed AB stress. 
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MATERIALS AND METHODS 
Reactor Operation 
A laboratory-scale sequencing batch reactor (SBR) had a working volume of 8 L, with 2 L of 
treated wastewater removed and replaced with synthetic influent wastewater every 6 h, 
resulting in a hydraulic retention time (HRT) of 24 h. The sludge age was approximately 24 
days.  The  synthetic influent wastewater contained either acetate or propionate as the sole 
carbon source (alternated on a fortnightly basis;  Lu et al., 2006) and orthophosphate (P-PO4
3-
 
 
) at concentrations of approximately 1100 mg chemical oxygen demand (COD) L
-1 
and 23 
mg P-PO4
3-  
L
-1 
respectively (see SI for further details).  The SBR was operated for EBPR, an 
activated sludge process for removing phosphate from wastewater.  It is appropriate to 
investigate because it is commonly used in full-scale WWTPs and the bacterial community 
and biochemical transformations involved are well characterised (Seviour et al., 2003).  The 
current study used granular activated sludge as the reactor biomass.  This is a novel activated 
 
sludge technology which selects for aggregates (>200 µm) which are larger than those 
occurring in conventional floccular activated sludge (de Kreuk et al., 2007). 
The operational parameters necessary for EBPR include introducing the wastewater into an 
anaerobic phase of operation, with an aerobic phase following.  Typically, during the 
anaerobic stage the carbon source is taken up and phosphate is released by the bacteria, then 
in the subsequent aerobic phase the phosphate is taken up by the bacteria, over and above that 
which was released in the anaerobic phase (Seviour et al., 2003).  Prior to dosing of 
pharmaceuticals the SBR was performing good EBPR for more than 6 months.  During 
dosing, the reactor operation did not change, except that the principal carbon source in the 
reactor feed was no longer alternated between acetate and propionate but rather only acetate 
was used in order to reduce the number of variables. OC and ABs were added as detailed 
below. 
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OC and AB dosing 
 
The OC and AB dosing for the SBR mirrored projected usage in the United Kingdom, as per 
Singer et al. (submitted), with stepwise dosing up to the pandemic peak.  OC and ABs were 
dissolved in sterile distilled water and added to autoclaved acetate feed.  The maximum 
amount of each AB and OC in the reactor influent was: 36 µg L
-1 
OC, 70 µg L
-1 
amoxicillin, 
30 µg L
-1 
erythromycin, and 10 µg L
-1 
levofloxacin.  During the 14-day OC-only dosing 
 
period the reactor influent contained 360 µg OC L
-1 
(see Table S1).  At the peak of the 
simulated pandemic the concentration of ABs and OC were ~2 to 20 × projected mean 
concentrations  in WWTPs as per Singer et al. (submitted), during a moderate pandemic (R0 
= 2.3, where R0 indicates the average number of infections generated by an infectious 
individual in a fully susceptible population) with conservative estimates of Tamiflu use 
within the populations, (30% of infected people utilise OC).  Although the experimental 
concentration of pharmaceuticals in the reactor were above mean projected levels (Singer et 
al., submitted), they reflect a realistic worst-case scenario. 
Measurement of OC 
 
OC was quantified from the influent and effluent during a single cycle of the SBR on the 
 
final day of each dosing regime.  Approximately 10 mL of each sample was filtered through a 
 
0.22 µm disposable filter (Millipore, Billerica, MA, USA) into glass GC vials and kept at -20 
o
C until measurement.  OC concentrations were measured by direct aqueous injection of the 
sample into an Agilent 6410B Triple Quad LC MS at the National Laboratory Services 
(Wales) (see SI for further details). 
Biochemical analyses 
 
Mixed liquor suspended solids (MLSS), effluent suspended solids (effluent SS) and mixed 
liquor volatile suspended solids (VSS) were measured according to standard methods 
(APHA, 1998).  Ammonium (N-NH4
+
), nitrate (N-NO3
-
), nitrite (N-NO2
-
), orthophosphate 
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(P-PO4
3-
) and acetate concentrations in the liquid phase were analysed at the AWMC 
Analytical Laboratory (Brisbane, QLD, Australia) (see SI for further details). 
Granule structure analyses 
Visual inspections of whole granules were performed using an Olympus SZH10 stereo- 
microscope with a DP70 digital camera.  Approximately 25 mL of mixed liquor was removed 
from the SBR at the end of the aerobic phase and photographed in a glass petri dish against a 
black background.  Volumetric size distribution of granules was determined by pumping 
approximately 30 mL of mixed liquor (again, removed at the end of the aerobic phase) 
through a Malvern laser light scattering instrument (Mastersizer 2000 series, Malvern 457 
Instruments, Worcestershire, UK). 
 
T-RFLP 
 
T-RFLP analysis of 16S rRNA genes was carried out as previously described  (Slater et al., 
 
2010) (see SI for further details). 
 
Fluorescence in situ hybridisation (FISH) 
 
Biomass samples were taken during the aerobic phase of the SBR and fixed in 4% 
paraformaldehyde in phosphate-buffered saline at 4
o
C for 2 h.  FISH was performed as 
described previously (Amann, 1995) (see SI for further details). 
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RESULTS 
 
OC degradation 
 
Over the experimental period there was evidence of varying rates of removal of OC (Figure 
 
1).  These were equivalent to between 2 and 41% removal per 6 h SBR cycle (estimated for 
each dosing period based on measured influent OC concentrations, four draw and fill cycles 
per day (Figure S1), and assuming a constant rate of removal for each dosing period).  There 
was a general, although not consistent, trend for removal rates to be lower in the latter part of 
the experiment (i.e. after day 35) than in the earlier part (Figure 1). 
Nutrient removal performance 
Phosphate levels from full-scale WWTP effluents are legally regulated.  The laboratory SBR 
was operating for biological phosphorus removal and thus this formed the basis for 
monitoring reactor function.  Effluent P-PO4
-3 
levels during the 40-day pre-pandemic 
simulation period and first 21 days of the simulated pandemic (i.e., 0.1% and 1% OC dosing) 
 
were between 2 and 7 mg L
-1 
(Figure 2).  Notably, effluent P-PO4
-3 
levels decreased to less 
than 1.2 mg L
-1 
by day 28, indicating a well-functioning reactor.  However, from day 33 at 
the beginning of the 100% OC-only dosing, effluent P-PO4
-3 
values became erratic and were 
typically high, reaching a maximum of 34 mg L
-1
, indicating reduced EBPR performance. 
This reduced EBPR during the dosing period was confirmed by other measures of 
performance.  Firstly, the anaerobic phosphate release (Figure S2; used by others previously 
as a measure of EBPR performance; He et al., 2008, Slater et al., 2010, Zilles et al., 2002). 
Secondly, complete anaerobic consumption of acetate, which occurred for the 40-day pre- 
pandemic period and throughout the simulated pandemic period, failed on day 56, when 
consumption became incomplete (data not shown).  Thirdly, nitrification (which occurred 
despite the operation of the SBR primarily for EBPR), as evidenced by aerobic nitrate 
production (Figure S3) decreased from over 0.85 mg N-NO3
- 
g
-1 
VSS for the pre-pandemic 
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period and the first 35 days of simulated pandemic to below 0.4 mg N-NO3
- 
g
-1 
VSS at the 
end of the 100% OC dosing period. 
Granule structure 
 
The mixed liquor suspended solids (MLSS; equivalent to cell dry weight) in the SBR was 
between 12.68 and 15.12 g L
-1 
from 7 days before dosing to day 56 (data not shown). 
Granule particle size distribution was between approximately 80 µm (10
th 
percentile) and 
1320 µm (90
th 
percentile), with a median granule size of approximately 620 µm (Figure S4). 
 
Neither of these measures showed significant trends over the experiment.  However, there 
were indications from light microscopy that some of the granules lost some structural 
integrity during the dosing as there was an appearance of fluffier material at days 49 and 58 
(Figure S5).  Additionally, there was evidence of an increase in the effluent SS from 
approximately 100 mg L
-1 
before dosing to approximately 400 mg L
-1 
on days 42 and 56 
(Figure S6), suggesting sludge settling was poorer due to granule biofilm disruption. 
Bacterial community structure 
Diversity indices derived from 16S rRNA T-RFLP data indicated that there were changes in 
the community structure over the dosing period, with the Shannon diversity index decreasing 
over the last 14 days of dosing (Figure 3).  This appeared to be a result of the development of 
a less even community structure (Figure S7) rather than the disappearance of particular 
operational taxonomic units (Figure S8).  Whilst there was therefore some evidence of 
change in diversity indices, i.e. those describing aggregate community characteristics, there 
appeared to be little change in the relative abundance of two of the model organisms 
commonly found in EBPR systems.  The relative abundance of a key organism responsible 
for EBPR, Candidatus “Accumulibacter phosphatis” (Hesselmann et al., 1999), was 27.1 % 
on day 0 (92% congruency score) and 22.8% on day 42 (end of 100% OC dosing; 96% 
congruency score), as assessed by quantitative FISH.  The relative abundance of a glycogen- 
11 
 
219  accumulating organism  and known  EBPR antagonist, Candidatus "Competibacter 
 
220  phosphatis" (Crocetti et al., 2002), was below 1% on days 0 and 42. 
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DISCUSSION 
 
This is the first study in which the removal of OC, microbial diversity, nutrient removal 
performance and granule structure has been tested in a simulated activated sludge system 
exposed to OC and ABs in pandemic-scenario dosing. 
There was up to 41% removal of OC per 6 h SBR cycle, with the most successful removal 
occurring in the first 35 days of dosing. It may be that in a real pandemic scenario, 35 days of 
significant removal at the beginning of an epidemic would reduce the amount of OC released 
into receiving waters. However, during the SBR operation there was no evidence of 
significant OC removal after day 35.  Hence, there does not appear to be sufficient selective 
pressure for the enrichment of OC-degraders in the system investigated. 
There was no evidence of any adverse effects on reactor performance during the first 28 days 
of simulated pandemic (i.e. up to 36 µg L
-1 
OC, 70 µg L
-1 
amoxicillin, 30 µg L
-1 
erythromycin, and 10 µg L
-1 
levofloxacin).  There was however evidence during and after the 
two-week high-OC dosing period (days 29 – 42; 360 µg L-1 OC) of a reduction in EBPR and 
nitrification, bacterial community diversity and disruption to granule structure. This evidence 
of ecotoxicity in a simulated WWTP complements, but also contrasts with other studies that 
found no OC toxicity in fresh water (Accinelli et al., 2010) and activated sludge performance 
(Straub, 2009; testing limited to COD removal only).  The positioning of the high OC-only 
dosing period in the middle of the pandemic scenario (i.e. dosing of OC and ABs) meant that 
we were not able to completely differentiate the causes of the perturbation to community 
structure and function; however, it is clear from this study that WWTPs may experience 
reduced efficiency during an influenza pandemic owing to high concentrations of bioactive 
pharmaceuticals, such as antivirals and antibiotics. 
The SBR chosen for this study had a relatively long history of stable EBPR performance (>6 
months).  EBPR failure has previously been shown to occur as a result of competition with 
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glycogen accumulating organisms (Bond et al., 1999) and from bacteriophage infection(Barr 
et al., 2010) (Barr et al., 2010), hence, the loss in reactor function in this study might not be 
due to pharmaceutical exposure.  However, as quantitative FISH analyses did not 
demonstrate a decrease in the relative abundance of Candidatus “Accumulibacter 
phosphatis”, as would be expected if bacterial competition or bacteriophage predation was to 
blame, it was concluded that pharmaceutical exposure was the more likely cause.  As the 
SBR was operated as a granular (rather than floccular) sludge, it remains untested whether 
floccular sludge would respond differently to such exposure.  Granular sludge systems do 
have some operational differences to floccular systems, such as longer sludge ages, higher 
mixed liquor suspended solids and lower available surface area, all of which might affect 
sludge-pharmaceutical interactions. 
It was only after dosing high concentrations of ABs and OC that effects on EBPR 
performance were noticed.  Therefore, it may be that it is only under severe pandemic 
scenarios that disruption to WWTPs is of concern.  Nonetheless, this research highlights the 
reality of this chemical risk to WWTP function and the need for additional mixed- 
pharmaceutical dosing studies in WWTP systems.  These will be important for optimising 
WWTP operation to contend with threats to WWTP function, and for understanding and 
modelling the release of pharmaceuticals to the environment. 
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Figure legends 
 
 
 
 
Figure 1.  Effluent OC concentration, showing observed values (filled circles) and predicted 
values assuming no degradation (open circles).  Dotted lines represent the ends of a particular 
dosing regime and indicate the OC dosing level as a percentage of the maximum dose. 
 
 
 
Figure 2.  Effluent P-PO4
-3 
concentrations, from flow injection analysis (filled circles) and 
colourimetric tests (open circles).  Dotted lines represent the ends of a particular dosing 
regime and indicate the OC dosing level as a percentage of the maximum dose. 
 
 
 
Figure 3.  Shannon diversity, H, derived from analysis of T-RFLP data. Dotted lines 
represent the ends of a particular dosing regime and indicate the OC dosing level as a 
percentage of the maximum dose. 
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Reactor Operation 
 
The synthetic feed introduced to the SBR at the beginning of each cycle comprised 
approximately 0.6 L solution A (autoclaved) and 1.3 L solution B. Solution A contained (g 
L
-1 
unless otherwise stated): NH4Cl (1.02), peptone (0.014), yeast (0.014), MgSO4.7H20 
(5.48), CaCl2.2H20 (0.588), nutrient solution after Smolders et al. (1994) (1 mL), allyl-n 
thiourea (ATU, a nitrification inhibitor; 0.014) and either NaCH3COO.3H20 (8.5) or 
CH3CH2COOH (2.646 mL) and 2M NaOH (8 mL) to provide identical mg COD L
-1
. 
Solution B contained (g L
-1
): K2HPO4 (0.132), KH2PO4 (0.103) and 2M NaOH (1.6 mL). 
Each cycle was 6 h, with a draw and fill (36 mins), an anaerobic phase (90), aerobic phase 
 
(232), waste (1), settle (1). The SBR was operated stably for EBPR for a period of 6 months 
before dosing, with effluent P concentrations consistently below 7 mg L
-1
. 
 
Oseltamivir Carboxylate (OC) measurement 
2 
 
 
The OC concentration in the samples was determined by high performance liquid 
chromatography tandem mass spectrometry (LCMSMS).  The system used was an Agilent 
1200 HPLC system coupled to the Agilent 6410B triple quadrupole mass spectrometer. 50 
 
µL of the aqueous samples was injected onto an ACE C18 column (2.1 mm i.d. × 150 mm 
length, 3 µm particle size) held at 45 
o
C. The mobile phase was 0.1% formic acid in 
deionised water (solvent A) and 0.1% formic acid in methanol (solvent B) starting at 15% 
solvent B and with the following solvent gradient at a flow rate of 0.3 mL min
-1
: 
3 
 
 
 
 
 
Time (mins) Solvent B (%) 
 
 
0.00 15 
 
 
10.00 70 
 
 
10.50 100 
 
 
11.50 100 
 
 
12.00 15 
 
 
Postime/equilibration time: 10 mins 
 
 
The Agilent triple quadrupole mass spectrometer was operated in positive electrospray ionisation 
mode. The nebuliser pressure, dry gas flow, dry gas temperature and Capillary voltage were held 
constant at 60 psig, 12 L min
-1
, 350 
o
C and 5000 V respectively. Data was acquired in multiple 
reaction monitoring mode monitoring the 285.1 → 197.1 and 285.1 → 138.1 transitions with 
collision energies of 4 V and 16 V respectively and a fragmentor voltage of 90 V. To check the 
performance of the method with real matrix samples a spike recovery was performed on surface 
water spiked at 30 ppb and 1000 ppb which returned recoveries of 110% and 107% and RSDs of 
6.3% and 3% respectively (n = 5). To check that there was consistent recovery over a range of 
relevant concentrations, a series of 10-fold dilutions of OC, from 0.018 to 1800 µg L
-1 
OC, in sterile 
distilled water were measured. All were within 9.7% of their predicted values. The limit of 
detection was 0.01 µg L
-1
. 
 
Biochemical analyses 
4 
 
 
Ammonium (N-NH4
+
), nitrate (N-NO3
-
), nitrite (N-NO2
-
), orthophosphate (P-PO4
3-
) were 
measured using either a Lachat QuikChem8000 flow injection analyser or, for P- PO4
3- 
only, 
a Reflectoquant
® 
P test (5-20 mg PO4
3- 
L
-1
; Merck KGaA, Darmstadt, Germany). Acetate 
concentrations were measured using an Agilent 7890A gas chromatograph (GC) with a FID 
detector and a Phenomenex ZB-FFAP column (30 m × 0.53 mm × 1.0 µm). 
 
 
T-RFLP 
 
 
Genomic DNA was subjected to PCR using the primers 63F (5' FAM (6-carboxyfluorescein) 
 
-labelled) and 1389R (Marchesi et al., 1998) and the purified PCR products subjected to 
digestion using the restriction enzyme MspI.  Digested products were ethanol precipitated 
and sent to the Australian Genome Research Facility (Glen Osmond, SA, Australia) to be 
analysed on an AB3730 Genetic Bioanalyzer (Applied Biosystems, Foster City, CA, USA) 
fitted with a 36 cm array and using the GS500(-250)LIZ standard. Data was processed and 
standardised and calculations of diversity indices, including Richness (S), the Shannon 
Diversity Index (H), and Shannon Evenness (J), were made as before (Slater et al., 2010)  . 
 
 
 
 
 
Fluorescence in situ hybridisation (FISH) 
 
 
EUBMIX (Daims et al., 1999) was used to target all bacteria, PAOMIX (Crocetti et al., 2000) 
 
was used to target Candidatus “Accumulibacter phosphatis”, and GAOQ989 (Crocetti et al., 
 
2002) and GBG2 (Kong et al., 2002) were used in conjunction to target Candidatus 
“Competibacter phosphatis”. The slides were viewed and images captured using a Zeiss LSM 
510 Meta confocal laser scanning microscope (CLSM) using a Zeiss Neofluar × 40/1.3 oil 
objective. Images were analysed using daime version 1.3.1 (Daims et al., 2006), with image 
segmentation carried out using default parameters. Biovolumes were calculated from 
5 
 
 
over 30 images acquired from 4 different wells of a slide using the biovolume fraction 
function (daime  user manual; http://www.microbial-ecology.net/daime/daime-manual.asp). 
The artefact rejection tool was set at a congruency threshold of 75%. 
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Table S1.  Dosing of pharmaceuticals. N.B.  Only OC was measured; the measured 
concentrations of OC were within 16% of their expected values for all except the lowest dose 
(i.e. 0.36 µg OC L
-1 
or 0.1% of the maximum dose), for which the measured values were 
different by between 27 and 75% of their expected values. 
 
 
 
Days from Dosing of pharmaceuticals in influent wastewater (µg L
-1
) 
 
start of dosing 
OC Amoxicillin Erythromycin Levofloxacin 
 
 
1-7 0.36 0.7 0.3 0.1 
 
 
8-14 0.36 0.7 0.3 0.1 
 
 
15-21 3.6 7 3 1 
 
 
22-28 36 70 30 10 
 
 
29-35 360 0 0 0 
 
 
36-42 360 0 0 0 
 
 
43-49 3.6 7 3 1 
 
 
50-56 0.36 0.7 0.3 0.1 
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Figure S1.  Simulated effluent OC concentrations based on measured influent OC 
concentrations and four SBR draw and fill occurrences per day, each with a volumetric 
exchange ratio of 1:4, and assuming no sorption or biological transformation (i.e. no removal 
of OC) by sludge. 
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Figure S2.  Anaerobic P-PO4
-3 
release (normalised to volatile suspended solids (VSS); 
 
analogous to cell dry weight). Whilst anaerobic release averaged greater than 13.5 mg P-PO4
-
 
3 
g
-1 
VSS for the 40 day pre-pandemic period and first 21 days of the simulated pandemic 
period, it went below 10 mg P-PO4
-3 
g
-1 
VSS in the 100% OC dosing period and had 
decreased to below 5 mg P-PO4
-3 
g
-1 
VSS by the end of the dosing period. Dotted lines 
represent the ends of a particular dosing regime and indicate the OC dosing level as a 
percentage of the maximum OC dose. 
 
 
. 
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Figure S3.  Aerobic nitrate production (normalised to volatile suspended solids (VSS); 
analogous to cell dry weight). Whilst aerobic nitrate production averaged over 0.85 mg N- 
NO3
- 
g
-1 
VSS for the pre-pandemic period and the first 35 days of simulated pandemic period 
(excluding outlier at 31 days before start of dosing), it had decreased to below 0.4 mg N-NO3
-
 
 
g
-1 
VSS by day 42 and there was no nitrate production by day 56.  Dotted lines represent the 
ends of a particular dosing regime and indicate the OC dosing level as a percentage of the 
maximum dose. 
10 
 
 
 
 
 
 
 
 
Figure S4.  Particle size distribution of granules, including 10
th 
(filled circles), 50
th 
(open 
circles) and 90
th 
(filled triangles) percentiles. Error bars represent standard error of the mean 
of three replicate measurements. Dotted lines represent the ends of a particular dosing 
regime and indicate the OC dosing level as a percentage of the maximum dose. 
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Figure S5.  Light microscopy images of granules against a black background taken on 
different days at different dosing regimes (indicated as the OC dosing level as a percentage of 
the maximum dose).  All images were taken at the same magnification. Scale bar (Day 13 
image) represents 1500 µm. 
12 
 
 
 
 
 
Figure S6.  Effluent suspended solids (SS).  Dotted lines represent the ends of a particular 
dosing regime and indicate the OC dosing level as a percentage of the maximum dose. 
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Figure S7.  Shannon evenness (J) derived from T-RFLP data. Dotted lines represent the 
ends of a particular dosing regime and indicate the OC dosing level as a percentage of the 
maximum dose. 
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Figure S8.  Richness (S) derived from T-RFLP data. Dotted lines represent the ends of a 
particular dosing regime and indicate the OC dosing level as a percentage of the maximum 
dose. 
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Reactor Operation 
 
The synthetic feed introduced to the SBR at the beginning of each cycle comprised 
approximately 0.6 L solution A (autoclaved) and 1.3 L solution B. Solution A contained (g 
L
-1 
unless otherwise stated): NH4Cl (1.02), peptone (0.014), yeast (0.014), MgSO4.7H20 
(5.48), CaCl2.2H20 (0.588), nutrient solution after Smolders et al. (1994) (1 mL), allyl-n 
 
thiourea (ATU, a nitrification inhibitor; 0.014) and either NaCH3COO.3H20 (8.5) or 
CH3CH2COOH (2.646 mL) and 2M NaOH (8 mL) to provide identical mg COD L
-1
. 
Solution B contained (g L
-1
): K2HPO4 (0.132), KH2PO4 (0.103) and 2M NaOH (1.6 mL). 
Each cycle was 6 h, with a draw and fill (36 mins), an anaerobic phase (90), aerobic phase 
(232), waste (1), settle (1). The SBR was operated stably for EBPR for a period of 6 months 
before dosing, with effluent P concentrations consistently below 7 mg L
-1
. 
 
Oseltamivir Carboxylate (OC) measurement 
 
 
The OC concentration in the samples was determined by high performance liquid 
chromatography tandem mass spectrometry (LCMSMS).  The system used was an Agilent 
1200 HPLC system coupled to the Agilent 6410B triple quadrupole mass spectrometer. 50 
 
µL of the aqueous samples was injected onto an ACE C18 column (2.1 mm i.d. × 150 mm 
length, 3 µm particle size) held at 45 
o
C. The mobile phase was 0.1% formic acid in 
deionised water (solvent A) and 0.1% formic acid in methanol (solvent B) starting at 15% 
solvent B and with the following solvent gradient at a flow rate of 0.3 mL min
-1
: 
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Time (mins) Solvent B (%) 
 
 
0.00 15 
 
 
10.00 70 
 
 
10.50 100 
 
 
11.50 100 
 
 
12.00 15 
 
 
Postime/equilibration time: 10 mins 
 
 
The Agilent triple quadrupole mass spectrometer was operated in positive electrospray ionisation 
mode. The nebuliser pressure, dry gas flow, dry gas temperature and Capillary voltage were held 
constant at 60 psig, 12 L min
-1
, 350 
o
C and 5000 V respectively. Data was acquired in multiple 
reaction monitoring mode monitoring the 285.1 → 197.1 and 285.1 → 138.1 transitions with 
collision energies of 4 V and 16 V respectively and a fragmentor voltage of 90 V. To check the 
performance of the method with real matrix samples a spike recovery was performed on surface 
water spiked at 30 ppb and 1000 ppb which returned recoveries of 110% and 107% and RSDs of 
6.3% and 3% respectively (n = 5). To check that there was consistent recovery over a range of 
relevant concentrations, a series of 10-fold dilutions of OC, from 0.018 to 1800 µg L
-1 
OC, in sterile 
distilled water were measured. All were within 9.7% of their predicted values. The limit of 
detection was 0.01 µg L
-1
. 
 
Biochemical analyses 
4 
 
 
Ammonium (N-NH4
+
), nitrate (N-NO3
-
), nitrite (N-NO2
-
), orthophosphate (P-PO4
3-
) were 
measured using either a Lachat QuikChem8000 flow injection analyser or, for P- PO4
3- 
only, 
a Reflectoquant
® 
P test (5-20 mg PO4
3- 
L
-1
; Merck KGaA, Darmstadt, Germany). Acetate 
concentrations were measured using an Agilent 7890A gas chromatograph (GC) with a FID 
detector and a Phenomenex ZB-FFAP column (30 m × 0.53 mm × 1.0 µm). 
 
 
T-RFLP 
 
 
Genomic DNA was subjected to PCR using the primers 63F (5' FAM (6-carboxyfluorescein) 
 
-labelled) and 1389R (Marchesi et al., 1998) and the purified PCR products subjected to 
digestion using the restriction enzyme MspI.  Digested products were ethanol precipitated 
and sent to the Australian Genome Research Facility (Glen Osmond, SA, Australia) to be 
analysed on an AB3730 Genetic Bioanalyzer (Applied Biosystems, Foster City, CA, USA) 
fitted with a 36 cm array and using the GS500(-250)LIZ standard. Data was processed and 
standardised and calculations of diversity indices, including Richness (S), the Shannon 
Diversity Index (H), and Shannon Evenness (J), were made as before (Slater et al., 2010)  . 
 
 
 
 
 
Fluorescence in situ hybridisation (FISH) 
 
 
EUBMIX (Daims et al., 1999) was used to target all bacteria, PAOMIX (Crocetti et al., 2000) 
 
was used to target Candidatus “Accumulibacter phosphatis”, and GAOQ989 (Crocetti et al., 
 
2002) and GBG2 (Kong et al., 2002) were used in conjunction to target Candidatus 
“Competibacter phosphatis”. The slides were viewed and images captured using a Zeiss LSM 
510 Meta confocal laser scanning microscope (CLSM) using a Zeiss Neofluar × 40/1.3 oil 
objective. Images were analysed using daime version 1.3.1 (Daims et al., 2006), with image 
segmentation carried out using default parameters. Biovolumes were calculated from 
5 
 
 
over 30 images acquired from 4 different wells of a slide using the biovolume fraction 
function (daime  user manual; http://www.microbial-ecology.net/daime/daime-manual.asp). 
The artefact rejection tool was set at a congruency threshold of75%. 
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Table S1.  Dosing of pharmaceuticals. N.B.  Only OC was measured; the measured 
concentrations of OC were within 16% of their expected values for all except the lowest dose 
(i.e. 0.36 µg OC L
-1 
or 0.1% of the maximum dose), for which the measured values were 
different by between 27 and 75% of their expected values. 
 
 
 
Days from Dosing of pharmaceuticals in influent wastewater (µg L 
-1
)
 
 
start of dosing 
 
OC Amoxicillin Erythromycin Levofloxacin 
 
 
1-7 0.36 0.7 0.3 0.1 
 
 
8-14 0.36 0.7 0.3 0.1 
 
 
15-21 3.6 7 3 1 
 
 
22-28 36 70 30 10 
 
 
29-35 360 0 0 0 
 
 
36-42 360 0 0 0 
 
 
43-49 3.6 7 3 1 
 
 
50-56 0.36 0.7 0.3 0.1 
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Figure S1.  Simulated effluent OC concentrations based on measured influent OC 
concentrations and four SBR draw and fill occurrences per day, each with a volumetric 
exchange ratio of 1:4, and assuming no sorption or biological transformation (i.e. no removal 
of OC) by sludge. 
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Figure S2.  Anaerobic P-PO4
-3 
release (normalised to volatile suspended solids (VSS); 
 
analogous to cell dry weight). Whilst anaerobic release averaged greater than 13.5 mg P-PO4
-
 
3 
g
-1 
VSS for the 40 day pre-pandemic period and first 21 days of the simulated pandemic 
period, it went below 10 mg P-PO4
-3 
g
-1 
VSS in the 100% OC dosing period and had 
decreased to below 5 mg P-PO4
-3 
g
-1 
VSS by the end of the dosing period. Dotted lines 
represent the ends of a particular dosing regime and indicate the OC dosing level as a 
percentage of the maximum OC dose. 
 
 
. 
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Figure S3.  Aerobic nitrate production (normalised to volatile suspended solids (VSS); 
analogous to cell dry weight). Whilst aerobic nitrate production averaged over 0.85 mg N- 
NO3
- 
g
-1 
VSS for the pre-pandemic period and the first 35 days of simulated pandemic period 
(excluding outlier at 31 days before start of dosing), it had decreased to below 0.4 mg N-NO3
-
 
 
g
-1 
VSS by day 42 and there was no nitrate production by day 56.  Dotted lines represent the 
ends of a particular dosing regime and indicate the OC dosing level as a percentage of the 
maximum dose. 
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Figure S4.  Particle size distribution of granules, including 10
th 
(filled circles), 50
th 
(open 
circles) and 90
th 
(filled triangles) percentiles. Error bars represent standard error of the mean 
of three replicate measurements. Dotted lines represent the ends of a particular dosing 
regime and indicate the OC dosing level as a percentage of the maximum dose. 
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Figure S5.  Light microscopy images of granules against a black background taken on 
different days at different dosing regimes (indicated as the OC dosing level as a percentage of 
the maximum dose).  All images were taken at the same magnification. Scale bar (Day 13 
image) represents 1500 µm. 
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Figure S6.  Effluent suspended solids (SS).  Dotted lines represent the ends of a particular 
dosing regime and indicate the OC dosing level as a percentage of the maximum dose. 
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Figure S7.  Shannon evenness (J) derived from T-RFLP data. Dotted lines represent the 
ends of a particular dosing regime and indicate the OC dosing level as a percentage of the 
maximum dose. 
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Figure S8.  Richness (S) derived from T-RFLP data. Dotted lines represent the ends of a 
particular dosing regime and indicate the OC dosing level as a percentage of the maximum 
dose. 
15 
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